| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Offering costs related to issuance of common stock | - | 0 |
| Net cash provided by financing activities | 14,576 | 11,492 |
| Net change in cash, cash equivalents and restricted cash | -153,644 | -210,819 |
| Cash and cash equivalents at beginning of period | 265,845 | - |
| Cash and cash equivalents at end of period | 112,201 | - |
Crinetics Pharmaceuticals, Inc. (CRNX)
Crinetics Pharmaceuticals, Inc. (CRNX)